Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

Cancer Cell

Volumn 24, Issue 6, 2013, Pages 751-765

  Perets, Ruth ^a   Wyant, GregoryA ^a   Muto, KatherineW ^a   Bijron, JonathanG ^a   Poole, BarishB ^a   Chin, KennethT ^a   Chen, JinYunH ^a   Ohman, AndersW ^a   Stepule, CoreyD ^a   Kwak, Soongu ^a   Karst, AlisonM ^a   Hirsch, MichelleS ^a   Setlur, SunitaR ^a   Crum, ChristopherP ^a   Dinulescu, DanielaM ^a   Drapkin, Ronny ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; SECRETORY CELL; UTERINE TUBE MUCOSA;

EID: 84891937100     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.10.013     Document Type: Article

References (55)

1. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., Stewart C., Fereday S., Caldas C., Defazio A., et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J.Pathol. 2010, 221:49-56.
2. Alsop K., Fereday S., Meldrum C., deFazio A., Emmanuel C., George J., Dobrovic A., Birrer M.J., Webb P.M., Stewart C., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J.Clin. Oncol. 2012, 30:2654-2663.
3. Bast R.C. Status of tumor markers in ovarian cancer screening. J.Clin. Oncol. 2003, 21(10 Suppl):200s-205s.
4. Bertucci M.C., Mitchell C.A. Phosphoinositide 3-kinase and INPP4B in human breast cancer. Ann. N Y Acad. Sci. 2013, 1280:1-5.
5. Bowen N.J., Logani S., Dickerson E.B., Kapa L.B., Akhtar M., Benigno B.B., McDonald J.F. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol. Oncol. 2007, 104:331-337.
6. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
7. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
8. Chene G., Tchirkov A., Pierre-Eymard E., Dauplat J., Raoelfils I., Cayre A., Watkin E., Vago P., Penault-Llorca F. Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin. Cancer Res. 2013, 19:2873-2882.
9. Cheung H.W., Cowley G.S., Weir B.A., Boehm J.S., Rusin S., Scott J.A., East A., Ali L.D., Lizotte P.H., Wong T.C., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 2011, 108:12372-12377.
10. Clark-Knowles K.V., Garson K., Jonkers J., Vanderhyden B.C. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp. Cell Res. 2007, 313:133-145.
11. Clark-Knowles K.V., Senterman M.K., Collins O., Vanderhyden B.C. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS ONE 2009, 4:e8534.
12. Collins I.M., Domchek S.M., Huntsman D.G., Mitchell G. Thetubal hypothesis of ovarian cancer: caution needed. Lancet Oncol. 2011, 12:1089-1091.
13. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 2005, 11:63-70.
14. Eppig J.T., Blake J.A., Bult C.J., Kadin J.A., Richardson J.E. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res. 2012, 40(Database issue):D881-D886. Mouse Genome Database Group.
15. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
16. Flesken-Nikitin A., Choi K.C., Eng J.P., Shmidt E.N., Nikitin A.Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 2003, 63:3459-3463.
17. Flesken-Nikitin A., Hwang C.I., Cheng C.Y., Michurina T.V., Enikolopov G., Nikitin A.Y. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 2013, 495:241-245.
18. Folkins A.K., Jarboe E.A., Saleemuddin A., Lee Y., Callahan M.J., Drapkin R., Garber J.E., Muto M.G., Tworoger S., Crum C.P. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 2008, 109:168-173.
19. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N.Engl. J. Med. 2009, 361:123-134.
20. Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., Barretina J., Lin W.M., Rameh L., Salmena L., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
21. Jazaeri A.A., Bryant J.L., Park H., Li H., Dahiya N., Stoler M.H., Ferriss J.S., Dutta A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 2011, 13:899-911.
22. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 2001, 29:418-425.
23. Karst A.M., Levanon K., Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl. Acad. Sci. USA 2011, 108:7547-7552.
24. Karst A.M., Levanon K., Duraisamy S., Liu J.F., Hirsch M.S., Hecht J.L., Drapkin R. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol. Oncol. 2011, 123:5-12.
25. Kim J., Coffey D.M., Creighton C.J., Yu Z., Hawkins S.M., Matzuk M.M. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. USA 2012, 109:3921-3926.
26. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F., Callahan M.J., Garner E.O., Gordon R.W., Birch C., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 2007, 31:161-169.
27. Kinross K.M., Montgomery K.G., Kleinschmidt M., Waring P., Ivetac I., Tikoo A., Saad M., Hare L., Roh V., Mantamadiotis T., et al. Anactivating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J.Clin. Invest. 2012, 122:553-557.
28. Kuhn E., Meeker A.K., Visvanathan K., Gross A.L., Wang T.L., Kurman R.J., Shih IeM. Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Mod. Pathol. 2011, 24:1139-1145.
29. Laury A.R., Hornick J.L., Perets R., Krane J.F., Corson J., Drapkin R., Hirsch M.S. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am. J. Surg. Pathol. 2010, 34:627-635.
30. Laury A.R., Perets R., Piao H., Krane J.F., Barletta J.A., French C., Chirieac L.R., Lis R., Loda M., Hornick J.L., et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am. J. Surg. Pathol. 2011, 35:816-826.
31. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., Saleemuddin A., Garber J., Birch C., Mou H., Gordon R.W., et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J.Pathol. 2007, 211:26-35.
32. Leeper K., Garcia R., Swisher E., Goff B., Greer B., Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 2002, 87:52-56.
33. Lesche R., Groszer M., Gao J., Wang Y., Messing A., Sun H., Liu X., Wu H. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002, 32:148-149.
34. Levanon K., Crum C., Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J.Clin. Oncol. 2008, 26:5284-5293.
35. Medeiros F., Muto M.G., Lee Y., Elvin J.A., Callahan M.J., Feltmate C., Garber J.E., Cramer D.W., Crum C.P. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006, 30:230-236.
36. Mittag J., Winterhager E., Bauer K., Grümmer R. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007, 148:719-725.
37. Mullany L.K., Fan H.Y., Liu Z., White L.D., Marshall A., Gunaratne P., Anderson M.L., Creighton C.J., Xin L., Deavers M., et al. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model invivo. Oncogene 2011, 30:3522-3536.
38. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., Weng L.P., Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J.Natl. Cancer Inst. 2000, 92:924-930.
39. Nichols K.E., Malkin D., Garber J.E., Fraumeni J.F., Li F.P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomarkers Prev. 2001, 10:83-87.
40. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
41. Perl A.K., Wert S.E., Nagy A., Lobe C.G., Whitsett J.A. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl. Acad. Sci. USA 2002, 99:10482-10487.
42. Przybycin C.G., Kurman R.J., Ronnett B.M., Shih IeM., Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am. J. Surg. Pathol. 2010, 34:1407-1416.
43. Quinn B.A., Brake T., Hua X., Baxter-Jones K., Litwin S., Ellenson L.H., Connolly D.C. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS ONE 2009, 4:e8404.
44. Roh M.H., Yassin Y., Miron A., Mehra K.K., Mehrad M., Monte N.M., Mutter G.L., Nucci M.R., Ning G., Mckeon F.D., et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod. Pathol. 2010, 23:1316-1324.
45. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CACancer J. Clin. 2012, 62:10-29.
46. Sood A.K., Sorosky J.I., Dolan M., Anderson B., Buller R.E. Distant metastases in ovarian cancer: association with p53 mutations. Clin. Cancer Res. 1999, 5:2485-2490.
47. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 1999, 21:70-71.
48. Szabova L., Yin C., Bupp S., Guerin T.M., Schlomer J.J., Householder D.B., Baran M.L., Yi M., Song Y., Sun W., et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 2012, 72:4141-4153.
49. Tacha D., Zhou D., Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl. Immunohistochem. Mol. Morphol. 2011, 19:293-299.
50. Traykova-Brauch M., Schönig K., Greiner O., Miloud T., Jauch A., Bode M., Felsher D.W., Glick A.B., Kwiatkowski D.J., Bujard H., et al. Anefficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat. Med. 2008, 14:979-984.
51. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., Coukos G., Crum C.C., Drapkin R., Etemadmoghadam D., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.
52. Veeck J., Ropero S., Setien F., Gonzalez-Suarez E., Osorio A., Benitez J., Herman J.G., Esteller M. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010, 28:e563-564. author reply e565-566.
53. Wu R., Hendrix-Lucas N., Kuick R., Zhai Y., Schwartz D.R., Akyol A., Hanash S., Misek D.E., Katabuchi H., Williams B.O., et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007, 11:321-333.
54. Wu R., Baker S.J., Hu T.C., Norman K.M., Fearon E.R., Cho K.R. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am. J. Pathol. 2013, 182:1391-1399.
55. Xu X., Wagner K.U., Larson D., Weaver Z., Li C., Ried T., Hennighausen L., Wynshaw-Boris A., Deng C.X. Conditional mutation of Brca1 inmammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 1999, 22:37-43.